NCT01397877 2023-09-06
ENDOPIK
ARCAGY/ GINECO GROUP
Phase 2 Completed
Clinical Trials
7 trialsNCT02117817 2022-07-28
Phase I BKM120/Abraxane in Solid Tumors, Expansion Phase Recurrent Endometrial or Ovarian Cancer
Rutgers, The State University of New Jersey
Phase 1 Withdrawn
NCT01623349 2021-02-10
Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer
Dana-Farber Cancer Institute
Phase 1 Completed
NCT01068483 2020-12-08
Safety of BKM120 Monotherapy in Advanced Solid Tumor Patients
Novartis
Phase 1 Completed
NCT01363232 2020-10-05
Safety, Pharmacokinetics and Pharmacodynamics of BKM120 Plus MEK162 in Selected Advanced Solid Tumor Patients
Array BioPharma
Phase 1 Completed
NCT01289041 2019-05-30
BKM120 as Second-line Therapy for Advanced Endometrial Cancer
Novartis
Phase 2 Completed
NCT01550380 2014-07-29
BKM120
University of Utah
Phase 2 Withdrawn